The 22nd IROAST Seminar－Development of polymeric nano/micro-particles for cancer theranostics－held on December 21, 2017
On December 21, 2017, Dr. Jaehong Key from the Department of Biomedical Engineering at Yonsei University, Korea, gave a talk at the 22nd IROAST Seminar. The seminar was organized by IROAST Associate Professor Aeju Lee, who introduced Dr. Key at the beginning of the seminar. Some forty students and faculty members attended the seminar for his interesting talk entitled “Development of Polymeric Nano/micro-particles for Cancer Theranostics,” given after he introduced his home university.
Please see the Report.
December 21(Thu), 2017: The 22nd IROAST Seminar－Development of polymeric nano/micro-particles for cancer theranostics
IROAST will hold the 22nd IROAST Seminar－Development of polymeric nano/micro-particles for cancer theranostics.
Please see the following for details of the seminar.
Most cancer deaths are due to cancer spreading from its primary site to other organs called metastasis. Thus, the early detection of cancer is very important to improve patient’s survival. Theranostics is a combination of the words “therapeutics” and “diagnostics”. Cancer theranostics represents a combinatorial diagnosis and therapeutic approach to cancer. The aim of cancer theranostics is to find early stage cancer and to effectively treat it at the same time. Nanoparticles can be a promising approach to deliver multiple components in a tiny nanostructure encapsulating imaging and therapy components with targeting ligands and stealth polymers completely changing pharmacokinetics and pharmacodynamics in the body. In this work, we demonstrate multifunctional nanoparticles for effective delivery of therapeutic and imaging agents by precisely adjusting size, shape, surface properties and mechanical stiffness. Herein the nanoparticles demonstrate high accumulation in cancer validated by multimodal imaging including MRI, PET-CT, and optical imaging. The engineered nanoparticles can be used in the early detection and effective treatment of primary cancer and metastasis.
This seminar is expected to attract a high level of interest. Everyone is welcome. We hope to see you at the seminar.